Research on the SARS-CoV-2 virus itself. Covers antiviral trials, antibody neutralization, viral escape, and rapid detection methods.
Researchers identified a new cellular protection pathway that targets a common vulnerability in several pandemic viruses, including Ebola and SARS-CoV-2. The study found that the MHC class II transactivator CIITA induces resistance by activating CD74, which disrupts viral entry into cells.
Dr. Christopher Basler receives $100,000 grant to study enzymes critical for SARS-CoV-2 replication and explore small molecule inhibitors as potential COVID-19 treatments. Early data suggests these drugs could be effective in slowing SARS-CoV-2 growth.
Researchers discovered that neutralizing antibodies provide protection from SARS-CoV-2 reinfection in a group of sailors who tested positive for these antibodies before embarking on a voyage. The high percentage of infected crew members highlights the importance of vaccination in preventing reinfections.
Researchers from Goethe University patented a method to interrupt SARS-CoV-2 signaling pathways using specific inhibitors, blocking viral replication. Tested cancer drugs showed promising results in laboratory experiments.
The study examined SARS-CoV-2 positivity rates among hospitalized children with no COVID-19 symptoms. Researchers found that approximately 21% of these patients tested positive for the virus.
Researchers detected SARS-CoV-2 genetic material in untreated wastewater samples from two treatment plants in Louisiana, USA. The virus was only found in untreated waste and not in treated wastewater, indicating standard processing may remove or destroy the virus.
Researchers found SARS-CoV-2 can infect human brain organoids, targeting cortical neurons and NPCs. The study provides evidence for the pathogenesis of neurological complications in COVID-19 patients.
A consortium of German researchers detects SARS-CoV-2 genetic material in treatment plants, estimating potential transmission risks. The study reveals 3-20 gene equivalents per millilitre of raw wastewater, indicating the degree of infection among residents.
Researchers at MassBiologics discovered a cross-reactive human monoclonal antibody to SARS-CoV-2 spike proteins, blocking ACE2 receptor binding and potentially preventing or limiting COVID-19 disease. The antibodies, in the sIgA isotype, exhibited higher binding affinity and neutralization activity than usual circulating IgG antibodies.
Researchers found that NK cell activation differed in patients with moderate and severe COVID-19. Adaptive NK cells, which have a greater ability to kill target cells, were observed in severely ill patients.
Researchers identified a strong and specific T cell response in COVID-19 patients who recovered from mild cases, suggesting a long-lived immunity. The study found that these patients' CD4+ T cells belonged to the Th1 category, which effectively fights viruses and stimulates antibody production.
DNA nanoswitches rapidly detect SARS-CoV-2 and other emerging viruses, including Zika and Dengue viruses. The low-cost platform can be performed within hours and provides a solution for resource-limited areas.
A new study maps natural killer cells in COVID-19 patients, finding specific characteristics of activation correlate with disease severity and adaptive NK cells with severe disease. The study suggests future research directions, including the role of NK cell responses in lung tissue and variability over time during SARS-CoV-2 infection.
Scientists developed four serological assays to detect SARS-CoV-2 antibodies and two for neutralizing antibodies, showing that antibody responses appear 5-6 days after symptoms, with neutralizing activity after 7-14 days. The assays were highly sensitive and specific, with varying levels of availability depending on equipment.
A new article by Dr. Ahmad Mourad explores how 'remote misses' in COVID-19 can create a false sense of invulnerability and security, potentially leading to increased risk. This phenomenon is linked to population-wide traumatic experiences and adaptive behavior.
Researchers found that genes associated with SARS-CoV-2 entry become more active with age, making heart cells vulnerable to damage. The study suggests that existing medicines can inhibit some of these proteins, and new treatments may be developed to protect the heart.
A new case series reports SARS-CoV-2 transmission on a commercial airline flight and among tourists, emphasizing the importance of preventive measures. The study provides valuable insights into the transmission dynamics of SARS-CoV-2, highlighting risk factors and control strategies to mitigate future outbreaks.
Researchers designed a novel receptor that binds to the SARS-CoV-2 virus, preventing it from entering cells. The decoy receptor has potent neutralizing activity against SARS-CoV-2 and also acts against SARS-CoV-1, a closely related virus.
Scientists have identified a small molecule that successfully inhibits influenza A, MERS-CoV, and SARS-CoV-2 in tissue culture and mice by blocking the interaction of AP2M1 with viral proteins. This finding suggests a possible broad-spectrum antiviral therapy to treat various viruses.
Researchers at MD Anderson Cancer Center found that some commercially available serological tests only detect N-protein antibodies, which may not indicate immunity to reinfection. S-RBD antibody detection is considered a better indicator of protection against COVID-19 reinfection.
Researchers developed a rapid molecular test called N1-STOP-LAMP that can diagnose SARS-CoV-2 with 100% accuracy in just 20 minutes. The test uses a portable machine and is highly efficient, making it suitable for settings with limited testing capabilities.
A team of scientists from Hokkaido University has successfully developed an adsorption-extraction technique to efficiently detect SARS-CoV-2 in untreated wastewater. This breakthrough method, using a surrogate virus like murine hepatitis virus, offers a fast and economical way to track the spread of COVID-19 at a larger scale.
Children accounted for only 1408 out of 129704 positive results, equal to 1% of total and 4% of tests carried out on them. The case fatality rate was estimated to be less than 1 in 200 (0.5%)
A study published in The FASEB Journal identifies a protein encoded by SARS-CoV-2 that may facilitate the virus's quick spread through cells. The research highlights key characteristics of the virus that could aid in the development of treatments for COVID-19.
Researchers at Michigan Tech and University of Edinburgh highlight the importance of understanding virus surface stability and interaction in various environmental conditions. They propose new techniques for studying surface chemistry, which could help design effective vaccines and treatments for SARS-CoV-2 and future pandemics.
Researchers at Northwestern University have uncovered a new vulnerability in the SARS-CoV-2 spike protein's binding site, which enables the virus to infect host cells. A negatively charged molecule can block this site, inhibiting viral transmission.
A study conducted at a large community hospital found that COVID-19 was prevalent among healthcare workers, with significant exposure rates reported. The findings underscore the importance of implementing robust infection control protocols to protect healthcare personnel and prevent further transmission.
A study published in PLOS ONE detected coronaviruses in bats and rodents, with increased detection rates found along the wildlife supply chain. The study highlights the importance of improving coronavirus surveillance and implementing targeted wildlife trade reform to minimize public health risks.
Researchers found that eight commercially available mouthwashes can inactivate Sars-Cov-2 viruses in cell culture experiments. The use of these mouthwashes could potentially reduce the viral load and risk of transmission, particularly in high-risk areas like the oral cavity and throat.
New research confirms pasteurisation inactivates SARS-CoV-2 virus in human milk, ensuring safe supply to preterm babies. Cold storage also doesn't impact the virus's stability, allowing mothers with COVID-19 to express and store milk safely.
The study found that asymptomatic and symptomatic patients shed high levels of viral RNA. It quantifies the amount of virus present in these individuals.
A new study found that absorbed plant miRNA MIR2911 in honeysuckle decoction can directly target SARS-CoV-2 genes and inhibit viral replication. Drinking the decoction accelerates negative COVID-19 patient conversion, suggesting a potential therapeutic strategy for treating SARS-CoV-2 infection.
The investigational vaccine induced neutralizing antibodies in mice, providing protection against SARS-CoV-2 infection. Additionally, mice challenged with the virus after a single dose showed protection against viral replication in the lung, indicating potential efficacy in humans.
Disulfiram, used to treat alcoholism, has shown potential against SARS-CoV-2 by inhibiting viral replication and reducing glutathione levels, while neratinib, an experimental breast cancer treatment, also demonstrates effectiveness in blocking coronavirus protease M pro.
A new study suggests that exposure to common cold coronaviruses can teach the immune system to recognize SARS-CoV-2, potentially leading to milder or more severe COVID-19 symptoms. The research found that memory helper T cells recognizing common cold coronaviruses also recognized matching sites on SARS-CoV-2.
Researchers created a new mouse model to study SARS-CoV-2 infection and disease, accelerating the development of treatments and vaccines. The model suggests that type I interferon signaling may play a pathological role in COVID-19 respiratory inflammation.
Studies found cross-reactive T cell epitopes in unexposed individuals, suggesting a potential for pre-existing immunity. The discovery sheds light on the mechanisms behind natural immunity to SARS-CoV-2.
Researchers identified a promising soluble variant of the human receptor for SARS-CoV-2 that competes with monoclonal antibodies. The variant, dubbed sACE2.v2.4, neutralizes both SARS-CoV-2 and SARS-CoV-1 in cell-based assays.
Researchers analyzed 48,635 coronavirus genomes, revealing the six strains of SARS-CoV-2 and their global spread. The study found that strain G and its related strains GR and GH are the most frequent, representing 74% of all gene sequences.
A new study published in Science Translational Medicine reveals that small molecule protease inhibitors can effectively block coronavirus replication and improve survival in MERS-CoV-infected mice. The findings suggest that these compounds could be investigated further as a potential therapeutic for human coronavirus infection.
Scientists have engineered antiviral compounds that can neutralize several types of coronaviruses, including COVID-19 and MERS. These compounds showed strong activity against SARS-CoV-2 and improved survival rates in mice infected with MERS.
Recent reports suggest a lower incidence of COVID-19 among high-altitude populations, however, current data is insufficient to confirm this association. The authors conclude that there is currently little supporting evidence for any protective benefit of genetic or nongenomic adaptation to high-altitude hypoxia.
The National Institutes of Health has awarded contracts to seven biomedical diagnostic companies to develop new lab-based and point-of-care tests for COVID-19. These tests will significantly increase the number, type, and availability of tests, meeting national demand estimated to be millions more tests per day.
Researchers found that moist heat treatment at 70°C for 60 minutes with 50% relative humidity does not damage the mask's structure or affect its function. This low-cost reprocessing strategy can be applied up to 10 times without compromising filtration, breathing resistance, fit, and comfort.
The study defines SARS-CoV-2 testing performance standards for safe student return to US residential campuses. It sets criteria for test accuracy and interpretation to minimize COVID-19 transmission risk.
Emergent psychiatric conditions associated with SARS-CoV-2 are linked to targetable biological mechanisms. Studies suggest a potential therapeutic target for these conditions.
A new study found that frontline healthcare workers with adequate PPE have a three-fold increased risk of positive SARS-CoV-2 test compared to the general population. Healthcare workers from BAME backgrounds were particularly at risk, with a fivefold increase in infection rate.
The California COVID Tracker will provide actionable viral genomic data to local public health jurisdictions, helping to inform policy decisions and reduce transmission. The program, launched in partnership with CZI and the CZ Biohub, aims to make SARS-CoV-2 tracing and analysis more efficient and accessible.
A researcher at Catholic University of America uses computer models to understand the structure of viruses, aiming to create effective antibodies against COVID-19. His findings suggest that mutated versions of existing antibodies could be produced to neutralize the virus.
A single-shot COVID-19 vaccine developed at Beth Israel Deaconess Medical Center raised neutralizing antibodies and protected non-human primates against SARS-CoV-2. The vaccine uses adenovirus serotype 26 to deliver the SARS-CoV-2 spike protein, stimulating immune responses.
Researchers created a new mouse model to study viral responses and test COVID-19 vaccines. The model, based on an adapted SARS-CoV-2 strain, showed promise in protecting vaccinated mice from disease.
A new rapid test detects neutralizing antibodies against Sars-Cov-2 in 18 hours, faster and more accessible than traditional methods. The test's accuracy is comparable to conventional tests, making it a reliable tool for determining immunity and vaccine effectiveness.
A cheaper, rapid, and accurate pooling strategy for RT-PCR-based detection of SARS-CoV-2 in clinical samples has been proposed. The assay has a significant impact on large-scale population screening, reducing testing costs by approximately 5-10 fold.
This observational study investigated age-related differences in nasopharyngeal SARS-CoV-2 levels in patients with mild to moderate COVID-19. The findings suggest varying levels of viral load across different age groups, which may impact treatment strategies and patient care.
Researchers found that severe COVID-19 is associated with endotheliitis and microangiopathy, leading to a multisystem inflammatory syndrome similar to Kawasaki disease. Additionally, obesity in adults under 65 years old increases the risk of intubation or death from COVID-19, but not for those over 65.
Researchers at Goethe University Frankfurt have identified a promising anti-viral strategy against COVID-19 by targeting the papain-like protease (PLpro) of SARS-CoV-2. Inhibiting PLpro can suppress viral production and strengthen innate immune response, offering a potential therapeutic approach to combat the virus.
A study found that some healthy individuals have immune cells capable of recognizing SARS-CoV-2 due to prior infections with 'common cold' coronaviruses. Cross-reactive T-helper cells may provide a protective effect, but could also lead to misdirected immune responses.
A team of international scientists reconstructed the evolutionary history of SARS-CoV-2 and found that the lineage has been circulating in bats for decades. The study suggests that preventing future pandemics requires better sampling within wild bats and real-time human disease surveillance systems.
A human immune system protein, LY6E-Protein, strongly inhibits corona viruses, including Sars-Cov-2, by preventing virus fusion with host cells. This finding may lead to the development of new therapies against coronaviruses.
An experimental COVID-19 vaccine demonstrated robust immune responses and rapid viral control in the upper and lower airways of rhesus macaques. The vaccine reduced replicating virus in the lungs and upper airway, which could limit disease progression and transmission.